PMID- 36378154
OWN - NLM
STAT- MEDLINE
DCOM- 20230203
LR  - 20230216
IS  - 1537-4513 (Electronic)
IS  - 1524-9557 (Linking)
VI  - 46
IP  - 2
DP  - 2023 Feb-Mar 01
TI  - Efficacy and Safety of Immune Checkpoint Inhibitors in Triple-negative Breast 
      Cancer: A Study Based on 41 Cohorts Incorporating 6558 Participants.
PG  - 29-42
LID - 10.1097/CJI.0000000000000447 [doi]
AB  - The project was designed to investigate the efficacy and safety of immune 
      checkpoint inhibitors (ICIs) in triple-negative breast cancer (TNBC). Electronic 
      databases were screened to identify relevant trials. The primary endpoints were 
      prognostic parameters and adverse events (AEs) through pooled rate, odds ratio, 
      and hazard ratio (HR) with 95% CI. Totally, 6558 TNBC patients from 41 cohorts 
      were included. The pooled pathologic complete response rate (odds ratio=2.03, 95% 
      CI: 1.35-3.06, P =0.0007) and event-free survival (HR=0.84, 95% CI: 0.73-0.96, P 
      =0.0100) of ICIs plus chemotherapy was higher than that of chemotherapy-alone in 
      early-stage TNBC. For metastatic TNBC, compared with chemotherapy-alone, the 
      addition of ICIs prolonged the progression-free survival (PFS) (HR=0.92, 95% CI: 
      0.88-0.96, P <0.0001); the improvement also existed in the following 3 subgroups: 
      programmed cell death-ligand 1 positive, race of White and Asian, and patients 
      without previous neoadjuvant or adjuvant chemotherapy; however, the benefit of 
      the combined regimen was not observed in overall survival (OS) (HR=0.95; 95% CI: 
      0.89-1.03, P =0.2127). In addition, the pooled rates of OS, PFS, and objective 
      response rate of ICIs plus chemotherapy were better than those of ICIs plus 
      targeted therapy or ICIs-alone. In the safety analysis, compared with 
      chemotherapy-alone, ICIs plus chemotherapy increased immune-related AEs and 
      several serious AE. The regimen of ICIs plus chemotherapy is promising in both 
      early-stage and metastatic TNBC, while the increased serious AE should not be 
      neglected. Furthermore, the pooled rates of OS, PFS, and objective response rate 
      of ICIs plus chemotherapy were better than those of ICIs plus targeted therapy or 
      ICIs-alone.
CI  - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Wu, Qing
AU  - Wu Q
AD  - Department of Oncology, Molecular Oncology Research Institute.
AD  - Department of Oncology, National Regional Medical Center, Binhai Campus of the 
      First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
FAU - Wu, Chunlan
AU  - Wu C
AD  - Department of Oncology, Molecular Oncology Research Institute.
AD  - Department of Oncology, National Regional Medical Center, Binhai Campus of the 
      First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
FAU - Xie, Xianhe
AU  - Xie X
AD  - Department of Oncology, Molecular Oncology Research Institute.
AD  - Department of Oncology, National Regional Medical Center, Binhai Campus of the 
      First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
AD  - Fujian Key Laboratory of Precision Medicine for Cancer, The First Affiliated 
      Hospital, Fujian Medical University, Fuzhou, Fujian Province, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20221116
PL  - United States
TA  - J Immunother
JT  - Journal of immunotherapy (Hagerstown, Md. : 1997)
JID - 9706083
RN  - 0 (Immune Checkpoint Inhibitors)
SB  - IM
MH  - Humans
MH  - *Immune Checkpoint Inhibitors/adverse effects
MH  - *Triple Negative Breast Neoplasms/drug therapy
MH  - Prognosis
MH  - Progression-Free Survival
MH  - Proportional Hazards Models
EDAT- 2022/11/16 06:00
MHDA- 2023/02/04 06:00
CRDT- 2022/11/15 10:43
PHST- 2022/06/30 00:00 [received]
PHST- 2022/08/17 00:00 [accepted]
PHST- 2022/11/16 06:00 [pubmed]
PHST- 2023/02/04 06:00 [medline]
PHST- 2022/11/15 10:43 [entrez]
AID - 00002371-202302000-00001 [pii]
AID - 10.1097/CJI.0000000000000447 [doi]
PST - ppublish
SO  - J Immunother. 2023 Feb-Mar 01;46(2):29-42. doi: 10.1097/CJI.0000000000000447. 
      Epub 2022 Nov 16.